Catalyst Pharmaceuticals, Inc.
CPRX
$14.89
$0.211.43%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 110.57M | 102.69M | 99.58M | 85.37M | 60.76M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 110.57M | 102.69M | 99.58M | 85.37M | 60.76M |
| Cost of Revenue | 17.78M | 97.83M | 16.00M | 13.51M | 15.29M |
| Gross Profit | 92.79M | 4.86M | 83.58M | 71.86M | 45.47M |
| SG&A Expenses | 42.04M | 33.56M | 28.40M | 29.72M | 14.09M |
| Depreciation & Amortization | 9.06M | 8.49M | 8.49M | 6.53M | 580.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 68.88M | 139.88M | 52.88M | 49.76M | 29.96M |
| Operating Income | 41.69M | -37.19M | 46.70M | 35.61M | 30.80M |
| Income Before Tax | 46.71M | -38.02M | 48.51M | 37.31M | 33.01M |
| Income Tax Expenses | 11.86M | -7.26M | 10.75M | 7.75M | 7.54M |
| Earnings from Continuing Operations | 34.84M | -30.76M | 37.76M | 29.57M | 25.47M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 34.84M | -30.76M | 37.76M | 29.57M | 25.47M |
| EBIT | 41.69M | -37.19M | 46.70M | 35.61M | 30.80M |
| EBITDA | 50.84M | -28.62M | 55.27M | 42.21M | 31.42M |
| EPS Basic | 0.33 | -0.29 | 0.36 | 0.28 | 0.24 |
| Normalized Basic EPS | 0.25 | -0.22 | 0.29 | 0.22 | 0.20 |
| EPS Diluted | 0.31 | -0.29 | 0.33 | 0.26 | 0.23 |
| Normalized Diluted EPS | 0.24 | -0.22 | 0.27 | 0.20 | 0.18 |
| Average Basic Shares Outstanding | 106.71M | 106.57M | 106.26M | 105.56M | 104.58M |
| Average Diluted Shares Outstanding | 113.76M | 106.57M | 113.67M | 113.99M | 113.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
